Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.

Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis. MASLD results from fat being disproportionately deposited in the liver. The goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment. The main questions it aims to answer are: * Does Niacin lower the fat deposition in the liver? * Does Niacin raise White Adipose Tissue storage of dietary fatty acids? Researchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response. Duration of study per participant: Up to 28 weeks

Eligibility

Inclusion Criteria:

* aged 20 to 80 years;
* diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country/ethnic group-specific criteria;

Exclusion Criteria:

1\) Presence of advanced fibrosis using any of the following criteria 1.1 (i.e., ≥ F3 based on liver stiffness \> 10kPa) using vibration-controlled transient elastography (FibroScan), 1.2 (Index for Liver Fibrosis \> 2.67) using Fibrosis-4 (FIB-4) which is a calculated score based on age and a combination of lab tests (aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\], and platelet count), 1.3 serum ALT \> 3 times the normal upper limit, 1.4 or signs of portal hypertension. 2) Other hepatic disease. 4) Overt cardiovascular or renal disease, cancer (other than non-melanoma skin cancer), or other uncontrolled medical conditions.

5\) Any contraindication to MRI. 6) Previous intolerance or allergy to nicotinic acid. 7) Having participated to a research study with exposure to radiation in the last two years before the start of the study.

8\) Being allergic to eggs 9) Smoking (\>1 cigarette/day) and/or consumption of \>2 alcoholic beverages per day.

10\) Women who are pregnant or breastfeeding.

Conditions4

Interventions2

Related trials

• "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients" — Ain Shams University
• Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy — Chinese University of Hong Kong
• Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients — National Cancer Center, Korea
• Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion — University of Cape Town
• Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy — Niels Fristrup
• Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal — University of Manitoba
• Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
• Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity — Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Browse More Trials